Indacaterol for the treatment of chronic obstructive pulmonary disease

Bibliography

• Cazzola M, Page C. Long-acting bronchodilators in COPD: where are we now and where are we going? Breathe 2014;10:110-20
   Google Scholar
• Beeh KM, Beier J. The short, the long and the “ultra-long”: why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther 2010;27:150-9
   PubMed Web of Science ®Google Scholar
• Braido F, Baiardini I, Cazzola M, et al. Long-acting bronchodilators improve health related quality of life in patients with COPD. Respir Med 2013;107:1465-80
   PubMed Web of Science ®Google Scholar
• Mäkelä MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med 2013;107:1481-90
   PubMed Web of Science ®Google Scholar
• Ágh T, Inotai A, Mészáros Á. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration 2011;82:328-34
   PubMed Web of Science ®Google Scholar
• Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 2011;105:435-41
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012;64:450-504
   PubMed Web of Science ®Google Scholar
• Matera MG, Page CP, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011;32:495-506
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008;63:831-8
   PubMed Web of Science ®Google Scholar
• Cazzola M, Spina D, Matera MG. The use of bronchodilators in stable chronic obstructive pulmonary disease. Pulm Pharmacol Ther 1997;10:129-44
   Web of Science ®Google Scholar
• Rossi A, Khirani S, Cazzola M. Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety. Int J Chron Obstruct Pulmon Dis 2008;3:521-9
   PubMedGoogle Scholar
• Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 2008;155:291-9
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Matera MG. Beta2-adrenoceptor agonists: current and future direction. Br J Pharmacol 2011;163:4-17
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG, Lötvall J. Ultra long-acting beta2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005;14:775-83
   PubMed Web of Science ®Google Scholar
• Cazzola M, Proietto A, Matera MG. Indacaterol for chronic obstructive pulmonary disease (COPD). Drugs Today (Barc) 2010;46:139-50
   PubMed Web of Science ®Google Scholar
• Cazzola M, Bardaro F, Stirpe E. The role of indacaterol for chronic obstructive pulmonary disease (COPD). J Thorac Dis 2013;5:559-66
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Rogliani P, Matera MG. Beta2-agonist therapy in lung disease. Am J Respir Crit Care Med 2013;187:690-6
   PubMed Web of Science ®Google Scholar
• Charlton SJ. Agonist efficacy and receptor desensitization: from partial truths to a fuller picture. Br J Pharmacol 2009;158:165-8
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65
   PubMed Web of Science ®Google Scholar
• Chung VC, Ma PH, Hui DS, et al. Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One 2013;8:e70784
   PubMedGoogle Scholar
• Cope S, Zhang J, Williams J, Jansen JP. Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis. BMC Pulm Med 2012;12:29
   PubMed Web of Science ®Google Scholar
• Cope S, Donohue JF, Jansen JP, et al. Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir Res 2013;14:100
   PubMed Web of Science ®Google Scholar
• Cope S, Capkun-Niggli G, Gale R, et al. Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of 2010chronic obstructive pulmonary disease–a network meta-analysis. Int J Chron Obstruct Pulmon Dis 2011;6:329-44
   PubMed Web of Science ®Google Scholar
• Mahler DA, Buhl R, Lawrence D, McBryan D. Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity. Pulm Pharmacol Ther 2013;26:348-55
   Google Scholar
• Han J, Dai L, Zhong N. Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials. BMC Pulm Med 2013;13:26
   PubMed Web of Science ®Google Scholar
• Wang J, Nie B, Xiong W, Xu Y. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. J Clin Pharm Ther 2012;37:204-11
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H. Comparison of indacaterol with tiotropium or twice-daily long-acting beta -agonists for stable COPD: a systematic review. Chest 2012;142:1104-10
   PubMed Web of Science ®Google Scholar
• Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013;1:524-33
   PubMed Web of Science ®Google Scholar
• Jiang FM, Liang ZA, Zheng QL, et al. Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review. Lung 2013;191:135-46
   Google Scholar
• Cazzola M, Calzetta L, Page CP, Matera MG. Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opin Drug Metab Toxicol 2014;10:129-37
   PubMed Web of Science ®Google Scholar
• Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-69
   PubMed Web of Science ®Google Scholar
• O’Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3:180-4
   PubMedGoogle Scholar
• Beier J, Beeh KM, Brookman L, et al. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther 2009;22:492-6
   PubMed Web of Science ®Google Scholar
• Beeh KM, Wagner F, Khindri S, Drollmann AF. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD 2011;8:340-5
   PubMedGoogle Scholar
• O’Donnell DE, Casaburi R, Vincken W, et al. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011;105:1030-6
   PubMed Web of Science ®Google Scholar
• Rossi A, Centanni S, Cerveri I, et al. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respir Med 2012;106:84-90
   Google Scholar
• Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011;140:331-4
   PubMed Web of Science ®Google Scholar
• Cazzola M, Segreti A, Stirpe E, et al. Energy expenditure and impact of bronchodilators in COPD patients. Respir Med 2010;104:1490-4
   Google Scholar
• Hataji O, Naito M, Ito K, et al. Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2013;8:1-5
   Google Scholar
• Rogliani P, Ora J, Ciaprini C, et al. Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. Respir Med 2014;108:307-13
   Google Scholar
• Cazzola M, Santus P, Castagna F, et al. Addition of an extra dose of salmeterol Diskus to conventional dose of salmeterol Diskus in patients with COPD. Respir Med 2002;96:439-43
   Google Scholar
• Cazzola M, Di Perna F, Noschese P, et al. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD. Eur Respir J 1998;11:1337-41
   PubMed Web of Science ®Google Scholar
• Hanania NA, Ambrosino N, Calverley P, et al. Treatments for COPD. Respir Med 2005;99(Suppl B):S28-40
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Long-acting beta2-adrenoceptor agonists: a smart choice for asthma? Trends Pharmacol Sci 2007;28:257-62
   Google Scholar
• Cazzola M, Segreti A, Stirpe E, et al. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. Respir Med 2013;107:107-11
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Ruggeri P, et al. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. Respir Med 2013;107:848-53
   Google Scholar
• Bernasconi M, Brandolese R, Poggi R, et al. Dose–response effects and time course of effects of inhaled fenoterol on respiratory mechanics and arterial oxygen tension in mechanically ventilated patients with chronic airflow obstruction. Intensive Care Med 1990;16:108-14
   Google Scholar
• Cazzola M, Matera MG. Long-acting beta2agonists as potential option in the treatment of acute exacerbations of COPD. Pulm Pharmacol Ther 2003;16:197-201
   Google Scholar
• Segreti A, Fiori E, Calzetta L, et al. The effect of indacaterol during an acute exacerbation of COPD. Pulm Pharmacol Ther 2013;26:630-4
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Bronchodilators: current and future. Clin Chest Med 2014;35:191-201
   PubMed Web of Science ®Google Scholar
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2014. Available from: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html [Last accessed 8 August 2014]
   Google Scholar
• National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. National Clinical Guideline Centre, London; 2010. Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/English [Last accessed 8 August 2014]
   Google Scholar
• Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011;155:179-91
   PubMed Web of Science ®Google Scholar
• Ohar JA, Donohue JF. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Semin Respir Crit Care Med 2010;31:321-33
   PubMed Web of Science ®Google Scholar
• Matera MG, Rogliani P, Cazzola M. Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2014;15:961-77
   PubMed Web of Science ®Google Scholar
• Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011;37:264-72
   PubMed Web of Science ®Google Scholar
• Cazzola M, Brusasco V, Centanni S, et al. Project PriMo: sharing principles and practices of bronchodilator therapy monitoring in COPD: a consensus initiative for optimizing therapeutic appropriateness among Italian specialists. Pulm Pharmacol Ther 2013;26:218-28
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Bettoncelli G, et al. Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. Respir Med 2012;106:249-56
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Cazzola M. Beta-adrenoceptor modulation in chronic obstructive pulmonary disease: present and future perspectives. Drugs 2013;73:1653-63
   PubMed Web of Science ®Google Scholar
• Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med 2013;173:1175-85
   PubMed Web of Science ®Google Scholar
• Mahler DA, D’Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012;67:781-8
   PubMed Web of Science ®Google Scholar
• Vincken W, Aumann J, Chen H, et al. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis 2014;9:215-28
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1:199-209
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013;1:51-60
   PubMed Web of Science ®Google Scholar
• Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42:1484-94
   PubMed Web of Science ®Google Scholar
• Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med 2013;107:1558-67
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Plaza V. Efficacy and safety of a fixed-dose combination of indacaterol and glycopyrronium for the treatment of COPD: a systematic review. Chest 2014;146:309-17
   PubMed Web of Science ®Google Scholar
• Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182(2):155-62
   PubMed Web of Science ®Google Scholar
• Dahl R, Chung KF, Buhl R, et al. INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010;65(6):473-9
   PubMed Web of Science ®Google Scholar
• Kornmann O, Dahl R, Centanni S, et al. NLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-µg Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011;37(2):273-9
   PubMed Web of Science ®Google Scholar
• Buhl R, Dunn LJ, Disdier C, et al. INTENSITY study investigators. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011;38(4):797-803
   PubMed Web of Science ®Google Scholar